Just one IPO priced this past week, as the annual August break rolls on. The big news came from NIO (NIO), the "Tesla of China" which filed to raise $1.8 billion in a US IPO. It was joined by three other Chinese companies preparing to go...read more
Aridis Pharmaceuticals, which is developing immunotherapies for antibiotic-resistant infections, raised $26 million by offering 2.0 million shares at $13, the low end of the range of $13 to $15. Aridis Pharmaceuticals plans to list on the Nasdaq under the...read more
Aridis Pharmaceuticals, which is developing immunotherapies for antibiotic-resistant infections, announced terms for its IPO on Monday. The San Jose, CA-based company plans to raise $28 million by offering 2.0 million shares at a price range of $13 to $15....read more
Aridis Pharmaceuticals, which is developing immunotherapies targeting pathogens associated with pneumonia, filed on Wednesday with the SEC to raise up to $35 million in an initial public offering. The San Jose, CA-based company was founded in 2003 and...read more
US IPO Weekly Recap: China readies a wave of US IPOs
Just one IPO priced this past week, as the annual August break rolls on. The big news came from NIO (NIO), the "Tesla of China" which filed to raise $1.8 billion in a US IPO. It was joined by three other Chinese companies preparing to go...read more
Immunotherapy biotech Aridis Pharmaceuticals prices IPO at $13, the low end of the range
Aridis Pharmaceuticals, which is developing immunotherapies for antibiotic-resistant infections, raised $26 million by offering 2.0 million shares at $13, the low end of the range of $13 to $15. Aridis Pharmaceuticals plans to list on the Nasdaq under the...read more
Pneumonia immunotherapy biotech Aridis Pharmaceuticals sets terms for $28 million IPO
Aridis Pharmaceuticals, which is developing immunotherapies for antibiotic-resistant infections, announced terms for its IPO on Monday. The San Jose, CA-based company plans to raise $28 million by offering 2.0 million shares at a price range of $13 to $15....read more
Pneumonia pathogen immunotherapy biotech Aridis Pharmaceuticals files for a $35 million IPO
Aridis Pharmaceuticals, which is developing immunotherapies targeting pathogens associated with pneumonia, filed on Wednesday with the SEC to raise up to $35 million in an initial public offering. The San Jose, CA-based company was founded in 2003 and...read more